Literature DB >> 26223704

Insurance company denial of payment and enforced changes in the type and dose of opioid analgesics for patients with cancer pain.

Kimberson Tanco1, Sofia E Bruera2, Eduardo Bruera1.   

Abstract

Opioids are the mainstay of treatment for moderate to severe cancer pain. The variations in average monthly cost can make it difficult for most patients to procure them without adequate insurance coverage. There are increasing numbers of denials of payment and statements made by insurance agents and other sources regarding inappropriate opioid use, resulting in severe pain and emotional distress for cancer patients and their families. This case series describes five events where the insurer was a major barrier to opioid access.

Entities:  

Keywords:  Barriers to pain management; Cancer pain; Insurance coverage; Insurance denial; Opioid analgesic

Mesh:

Substances:

Year:  2014        PMID: 26223704     DOI: 10.1017/S1478951514000091

Source DB:  PubMed          Journal:  Palliat Support Care        ISSN: 1478-9515


  3 in total

1.  Challenges to Opioid Prescription Access among Patients with Advanced Cancer.

Authors:  Marieberta Vidal; Akhila Reddy; EdenMae Rodriguez; Minjeong Park; Diane Liu; Eduardo Bruera
Journal:  J Palliat Med       Date:  2019-02       Impact factor: 2.947

2.  Patterns of Opioid Prescription, Use, and Costs Among Patients With Advanced Cancer and Inpatient Palliative Care Between 2008 and 2014.

Authors:  Sriram Yennurajalingam; Zhanni Lu; Suresh K Reddy; EdenMae C Rodriguez; Kristy Nguyen; Marie J Waletich-Flemming; Kyu-Hyoung Lim; Aksha Memon; Nhu-Nhu Nguyen; Kristy W Rofheart; Guoqin Wang; Srikanth Reddy Barla; Jimin Wu; Janet L Williams; Eduardo Bruera
Journal:  J Oncol Pract       Date:  2018-11-29       Impact factor: 3.840

3.  What if Acupuncture Were Covered by Insurance for Pain Management? A Cross-Sectional Study of Cancer Patients at One Academic Center and 11 Community Hospitals.

Authors:  Kevin T Liou; Tony K W Hung; Salimah H Meghani; Andrew S Epstein; Q Susan Li; Sally A D Romero; Roger B Cohen; Jun J Mao
Journal:  Pain Med       Date:  2019-10-01       Impact factor: 3.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.